Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza

  • Technology appraisal guidance
  • TA158
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The assessment report for this appraisal was prepared by the School of Health and Related Research (ScHARR), University of Sheffield.

  • Tappenden P et al. Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of existing guidance on the clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza), February 2008.

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Manufacturers, or sponsors, and professional or specialist and patient or carer groups were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

  • Alliance Pharmaceuticals

  • GlaxoSmithKline

  • Roche Products

Professional or specialist and patient or carer groups:

  • Diabetes UK

  • British Thoracic Society

  • General Practice Airways Group (GPIAG)

  • Health Protection Agency

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal Pharmaceutical Society

Other consultees

  • Department of Health

  • Monmouthshire LHB

  • Newham PCT

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal)

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • National Public Health Service for Wales

  • NHS Quality Improvement Scotland

  • Alliance Pharmaceuticals

  • GlaxoSmithKline

  • Roche Products

  • National Coordinating Centre for Health Technology Assessment

  • ScHARR

The following people were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of existing guidance on the clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza) by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Douglas Fleming, Unit Director, The Birmingham Research Unit, Royal College of General Practitioners, nominated by Royal College of General Practitioners – clinical specialist.

  • Dr John Watson, Consultant Epidemiologist, Head of the Respiratory Diseases Department, Health Protection Agency, nominated by nominated by Health Protection Agency – clinical specialist.

  • Mr Kail Gunaratnam, nominated by Diabetes UK – patient expert.

ISBN: 978-1-4731-6511-3